Bioinformatics analysis combined with experimental validation to explore the mechanism of XianLing GuBao capsule against osteoarthritis

Ethnopharmacological relevance: XianLing GuBao Capsule (XLGB) is often used to treat osteoarthritis (OA), osteoporosis, fractures, and other musculoskeleton disorders. However, the molecular mechanism of XLGB for treating OA is still unclear. Aim of the study: This study set out to uncover the molecular mechanism underlying the treatment of osteoarthritis with XLGB. Materials and methods: Disease genes were obtained from CTD, DisGeNET, and GeneCards databases, and XLGB drug targets were obtained from ETCM and target genes predicted by XLGB metabolic components reported in the literature. Then we used the Venn diagram viewer to extract disease and drug intersection genes as potential therapeutic genes for Protein-protein interaction (PPI), GO terminology, and KEGG pathway analysis. Subsequently, we performed qRT-PCR, Western blot and histological analysis to validate the therapeutic effect of XLGB against OA and its molecular mechanism. Results: A total of 1039 OA genes and 949 XLGB target genes were collected, and finally 188 potential therapeutic target genes were obtained. PPI network analysis indicated that the main target genes for XLGB to treat OA include Akt1, Mapk3, Il-6, Il-1 beta, Ptgs2, Mmp9, etc. The results of KEGG and GO enrichment analysis suggested that XLGB may treat OA by anti-inflammatory and reducing extracellular matrix degradation. In vitro, XLGB down regulated the expressions of Mmp3, Mmp9, Mmp12, Mmp13, Cox-2, Il-6, increased the expression of Collagen II and Sox9. Mechanistically, XLGB inhibits the activation of PI3K/AKT/NF-kappa B and MAPK pathways. Moreover, the results of animal experiments indicated that XLGB reduced cartilage destruction, bone resorption, and synovitis in osteoarthritic rats. Conclusions: XLGB has a protective effect against OA by suppressing PI3K/AKT/NF-kappa B and MAPK signaling. Our study provides a theoretical basis for XLGB in the treatment of osteoarthritis.

Automated summary

This study investigates the molecular mechanism of XianLing GuBao Capsule (XLGB) in treating osteoarthritis (OA). Through analyzing disease genes and XLGB targets, it is found that XLGB may treat OA by anti-inflammatory and reducing extracellular matrix degradation mechanisms. Experimental results show that XLGB suppresses PI3K/AKT/NF-kappa B and MAPK signaling pathways, leading to reduced cartilage destruction, bone resorption, and synovitis in osteoarthritic rats.